NEW YORK, June 2 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc., a closely held company. The full 56-page report can be found at www.crystalra.com.
GenSpera, Inc. ("GenSpera" or "the Company") is a development-stage biotechnology company focused on the discovery and development of prodrug cancer therapies. A prodrug is an inactive precursor of a drug that is converted into its active form at a targeted site. The Company has developed a novel approach to chemotherapy using a prodrug to deliver a potent, cell-killing agent to tumor sites while avoiding toxicity in healthy, non-cancerous cells. GenSpera's prodrugs target cancer cells in one of two ways: (1) by targeting tumor-associated blood vessels; or (2) by targeting tumors directly.
The Company's lead prodrug candidate, G-202, is designed to attack existing tumor vasculature, potentially debilitating the tumor's nutrient supply and causing cancer regression without affecting normal tissues within the body. In preclinical evaluation, G-202 demonstrated anti-tumor effects on the growth of breast, renal, bladder, and prostate cancers. Due to G-202's specific mechanism of action as well as its solid preclinical breast cancer data, GenSpera has selected breast cancer as the initial clinical focus, and intends to submit an Investigational New Drug (IND) application for G-202 during the second quarter 2009. Further, to prepare for clinical trials, the Company has formulated a Phase I clinical plan for G-202 together with investigators at
The Company's technology can also be used to attack cancer cells dir
|SOURCE Crystal Research Associates, LLC|
Copyright©2009 PR Newswire.
All rights reserved